4.8 Article

Depressive symptoms in cognitively unimpaired older adults are associated with lower structural and functional integrity in a frontolimbic network

Journal

MOLECULAR PSYCHIATRY
Volume 27, Issue 12, Pages 5086-5095

Publisher

SPRINGERNATURE
DOI: 10.1038/s41380-022-01772-8

Keywords

-

Funding

  1. European Union [667696]
  2. Institut National de la Sante et de la Recherche Medicale
  3. Region Normandie
  4. Fondation MMA des Entrepreneurs du Futur
  5. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant) [U01 AG024904]
  6. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  7. National Institute on Aging
  8. National Institute of Biomedical Imaging and Bioengineering
  9. AbbVie
  10. Alzheimer's Association
  11. Alzheimer's Drug Discovery Foundation
  12. Araclon Biotech
  13. BioClinica, Inc.
  14. Biogen
  15. Bristol-Myers Squibb Company
  16. CereSpir, Inc.
  17. Cogstate
  18. Eisai Inc.
  19. Elan Pharmaceuticals, Inc.
  20. Eli Lilly and Company
  21. EuroImmun
  22. F. Hoffmann-La Roche Ltd
  23. company Genentech, Inc.
  24. Fujirebio
  25. GE Healthcare
  26. IXICO Ltd.
  27. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  28. Johnson & Johnson Pharmaceutical Research & Development LLC.
  29. Lumosity
  30. Lundbeck
  31. Merck Co., Inc.
  32. Meso Scale Diagnostics, LLC.
  33. NeuroRx Research
  34. Neurotrack Technologies
  35. Novartis Pharmaceuticals Corporation
  36. Pfizer Inc.
  37. Piramal Imaging
  38. Servier
  39. Takeda Pharmaceutical Company
  40. Transition Therapeutics
  41. Canadian Institutes of Health Research

Ask authors/readers for more resources

Subclinical depressive symptoms are associated with increased risk of Alzheimer's disease, and this study found that these symptoms are linked to neurodegenerative changes in the brain.
Subclinical depressive symptoms are associated with increased risk of Alzheimer's disease (AD), but the brain mechanisms underlying this relationship are still unclear. We aimed to provide a comprehensive overview of the brain substrates of subclinical depressive symptoms in cognitively unimpaired older adults using complementary multimodal neuroimaging data. We included cognitively unimpaired older adults from the baseline data of the primary cohort Age-Well (n = 135), and from the replication cohort ADNI (n = 252). In both cohorts, subclinical depressive symptoms were assessed using the 15-item version of the Geriatric Depression Scale; based on this scale, participants were classified as having depressive symptoms (>0) or not (0). Voxel-wise between-group comparisons were performed to highlight differences in gray matter volume, glucose metabolism and amyloid deposition; as well as white matter integrity (only available in Age-Well). Age-Well participants with subclinical depressive symptoms had lower gray matter volume in the hippocampus and lower white matter integrity in the fornix and the posterior parts of the cingulum and corpus callosum, compared to participants without symptoms. Hippocampal atrophy was recovered in ADNI, where participants with subclinical depressive symptoms also showed glucose hypometabolism in the hippocampus, amygdala, precuneus/posterior cingulate cortex, medial and dorsolateral prefrontal cortex, insula, and temporoparietal cortex. Subclinical depressive symptoms were not associated with brain amyloid deposition in either cohort. Subclinical depressive symptoms in ageing are linked with neurodegeneration biomarkers in the frontolimbic network including brain areas particularly sensitive to AD. The relationship between depressive symptoms and AD may be partly underpinned by neurodegeneration in common brain regions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available